Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET)

By M. J. Leon, A. Convit, Oliver T. Wolf, C. Tarshish, S. Desanti, H. Rusinek, W. Tsui, Emad Kandil, Adam J. Scherer, A. Roche and 9 more. Proceedings of the National Academy of Sciences of the United States of America, 2001

660 citations recorded by the source corpus.

Subfields: Physiology, Psychiatry and Mental health, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/7d5082b7ad7e8c1cffff9dd59db1cc6527d15871

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Physiology

In Psychiatry and Mental health

In Pulmonary and Respiratory Medicine

Citations in the corpus

Multi-modal techniques for diagnosis and prognosis of Alzheimer’s disease (2009, result): “Additionally, although its accuracy has not been thoroughly compared with that of other biomarkers assessed in the same subjects, fluorodeoxyglucose PET has been reported to predict conversion from cognitive normalcy to mild cognitive impairmen”
Clinical biomarkers in drug discovery and development (2003, background): “For example, poor correlations can be found between early biomarkers and gold-standard neuropsychiatric assessments during the early stages of neurodegenerative diseases such as Alzheimer's disease, in which the disease can progress asymptomatically for many year”
The effects of stress and stress hormones on human cognition: Implications for the field of brain and cognition. (2007, background): “…has been confirmed on many occasions (Convit et al., 1995; Convit et al., 1995; Convit, Wolf, Tarshish, & de Leon, 2003; de Leon et al., 1995; de Leon et al., 2001; de Leon et al., 1993; Golomb et al., 1994; Golomb et al., 1994; Hackert et al., 2002; Lupien et al., 1998; Reiman et al., 1998;…”
The Brain's Default Network (2008, background): “Patients with AD show a speciﬁc anatomic pattern of reduced metabolism relative to age-matched healthy peers (Benson et al. 1983, Kumar et al. 1991, Herholz 1995, Minoshima et al. 1997, de Leon et al. 2001, Alexander et al. 2002, F IG .”
Brain imaging in Alzheimer disease. (2012, background): “…severe or consistent hypometabolism has been identified in MCI patients, some of whom were found on follow-up examination to have converted to AD (Arnaiz et al. 2001; de Leon et al. 2001; Jagust et al. 2002, 2007; Chetelat et al. 2003; Caselli et al. 2008; Langbaum et al. 2009; Landau et al. 2010).”
Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: An fMRI study (2005, background): “Functional imaging in MCI with FDG PET shows decreased resting state metabolism associated with cognitive decline in hippocampal regions and posterior cingulate cortex [Chetelat et al., 2003; De Santi et al., 2001].”
Discrimination between Alzheimer Dementia and Controls by Automated Analysis of Multicenter FDG PET (2002, background): “High sensitivity for very early AD is evident from stud- ies of asymptomatic subjects at high genetic risk for AD, which showed FDG PET abnormalities in areas typical for AD (Reiman et al., 1996; Small et al., 2000; de Leon et al., 2001).”
Regional coherence changes in the early stages of Alzheimer's disease: A combined structural and resting-state functional MRI study (2007, background): “Many PET studies have consistently shown reduced resting metabolism in the PCC/ PCu in subjects with AD (Buckner et al., 2005; Leon et al., 2001; Salmon et al., 2000; Volkow et al., 2002) or cognitively intact subjects with genetic susceptibility to AD (Reiman et al., 1996; Small et al., 2000).”